Investment Rating - The report indicates a positive outlook for the agriculture, forestry, animal husbandry, and fishery sectors, with a focus on improving profitability driven by declining feed costs and increased production scale [1][11]. Core Insights - The overall agricultural sector has seen a revenue increase of 6.12% year-on-year in H1 2025, reaching 614.8 billion yuan, with a significant profit increase of 198% to 27 billion yuan, primarily due to the recovery of the pig farming sector [1][11]. - The pig farming sector is experiencing a seasonal price decline, yet remains profitable due to reduced feed costs and increased production efficiency [2][28]. - The poultry farming sector has shown mixed performance, with revenue slightly declining by 0.29% in H1 2025, but net profit improved by 6.43% due to lower costs [3][21]. - The seed sector reported a revenue increase of 5.05% in H1 2025, although net profit turned negative, indicating challenges in seed sales due to falling grain prices [4][21]. Summary by Sections Industry Overview - Feed prices have been on a downward trend, improving overall farming costs. Pig prices have remained stable year-on-year, while poultry prices have been low but profitable across the supply chain. The agricultural product supply-demand balance is easing, with major product prices at low levels [1][11]. - In H1 2025, the sector achieved revenues of 614.8 billion yuan and net profits of 27 billion yuan, with significant contributions from the pig farming sector [1][11]. Pig Farming - In 2024, pig supply is expected to decrease, with prices showing seasonal trends. Despite a decline in prices post-October, the sector remains profitable. In Q1 2025, the average price was 15.01 yuan/kg, up 3.90% year-on-year, while Q2 saw a price drop to 14.56 yuan/kg, down 10.94% year-on-year [2][28]. - The pig farming sector generated revenues of 248.6 billion yuan in H1 2025, a 15.67% increase, with net profits soaring by 1551% to 17.1 billion yuan [2][28]. Poultry Farming - The poultry sector's revenue in H1 2025 was 33.7 billion yuan, a slight decline of 0.29%, but net profit increased by 6.43% to 1 billion yuan due to lower costs [3][21]. - The white feather chicken segment remains stable despite low prices, while the yellow feather chicken segment is recovering from previous losses [3][21]. Seed Sector - The seed sector reported revenues of 8.87 billion yuan in H1 2025, a 5.05% increase, but net profit turned negative, indicating challenges in the market [4][21].

8月29日晚间，天康生物交出一份漂亮的半年报，整体看公司营收净利润双双增长，经营性净现金流翻番，毛利率净利 率双增，资产负债率降至50%以下。 具体看，天康生物上半年实现营业收入88.47亿元，同比增长10.68%；归母净利润3.38亿元，同比增长22.27%；扣非归 母净利润3.14亿元，同比增长16.17%；基本每股收益0.25元。 从各项财务指标看，公司上半年加权净资产收益率为4.73%，同比提高0.49个百分点；销售毛利率为12.07%，同比提高 0.58个百分点；销售净利率4.63%，同比提高1.13个百分点。公司造血能力大幅提高，上半年经营性净现金流入16.19亿 元，去年同期为7.73亿元，同比增长109.44%。期末资产负债率为47.03%，相比去年末大幅下降4.46个百分点。 从单季度看，天康生物二季度实现营收46.66亿元，环比增长11.63%；实现归母净利润为1.9亿元，环比增长28.35%；销 售毛利率为12.29%，环比提高0.47个百分点。 另一方面，公司的油脂加工及玉米收储业务大幅好转，上半年公司植物蛋白及油脂加工业务量价齐升，实现销售收入 14.49亿元，同比上升97.60%， ...

Core Viewpoint - The report indicates that Tiankang Biological (002100) has shown steady revenue growth and improved profitability in H1 2025, with a buy rating recommended by China Galaxy Securities [1][2]. Financial Performance - In H1 2025, the company's revenue reached 8.847 billion yuan, a year-on-year increase of 10.68%, with net profit attributable to shareholders at 338 million yuan, up 22.27% year-on-year [2]. - For Q2 2025, revenue was 4.666 billion yuan, also reflecting a 10.68% year-on-year growth, but net profit decreased by 14.59% to 190 million yuan [2]. - The comprehensive gross margin for H1 2025 was 12.07%, an increase of 0.58 percentage points year-on-year, while the expense ratio decreased to 7.15% [2]. Business Segments - The revenue contributions from various segments in H1 2025 included pig farming (2.849 billion yuan, -0.95% YoY), feed (2.434 billion yuan, -14.24% YoY), agricultural product processing (1.449 billion yuan, +97.6% YoY), veterinary biological products (482 million yuan, -3.67% YoY), and corn silage (1.305 billion yuan, +72.32% YoY) [2][3]. - The company aims to achieve a pig output target of 3.5 to 4 million heads in 2025, representing a year-on-year increase of 15.57% to 32.08% [3]. Research and Development - In H1 2025, the company invested 113 million yuan in R&D, a decrease of 26.85% year-on-year, with new products expected to drive future growth in the vaccine business [4]. - The targets for animal vaccines and feed sales in 2025 are set at 2.4 billion milliliters and 2.9 million tons, respectively, indicating growth of 16.28% and 2.9% year-on-year [4]. Investment Outlook - The company is positioned as an integrated farming enterprise with stable growth in feed and veterinary medicine businesses, alongside a positive outlook for pig farming due to ongoing cost optimization [4]. - EPS forecasts for 2025 and 2026 are 0.54 yuan and 0.68 yuan, respectively, with corresponding PE ratios of 12 times and 10 times [4].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The agricultural sector's profit growth in H1 2025 is driven by the recovery of the breeding chain, with a revenue of 569.91 billion yuan, up 9.28% year-on-year, and a net profit of 25.79 billion yuan, up 193.46% year-on-year [12][19] - The pig price is expected to rise in H2 2025, supported by both fundamental and policy factors, improving the investment logic for pig farming [21] - The pet food sector continues to thrive, with domestic brands gaining market share due to consumption upgrades and tariff barriers [22] Summary by Sections Weekly Observation - The recovery of the breeding chain has driven significant profit growth in the agricultural sector for H1 2025, with a notable increase in net profit and revenue [12][19] - The average price of pigs in H1 2025 was 14.81 yuan/kg, down 4.00% year-on-year, but profitability improved due to lower breeding costs and increased output from leading companies [12][19] Weekly Viewpoint - The investment logic for pig farming is improving, with expected price increases in H2 2025 due to supply and demand dynamics [21] - The feed sector benefits from strong domestic and overseas demand, with recommendations for companies like Haida Group and New Hope [21] - The pet food market is projected to grow significantly, with domestic brands strengthening their position [22] Market Performance (8.25-8.29) - The agricultural index outperformed the market by 1.18 percentage points, with a 2.02% increase in the agricultural index compared to a 0.84% rise in the Shanghai Composite Index [24][27] - Leading stocks included Aonong Biological (+22.67%), Yuanfei Pet (+15.71%), and Xiaoming Co. (+10.86%) [24][29] Price Tracking (8.25-8.29) - The average price of pigs was 13.66 yuan/kg, with a slight decrease from the previous week, while the average price of beef increased to 65.05 yuan/kg [31][39] - The price of corn futures rose by 1.39% to 2187.00 yuan/ton, while soybean meal futures fell by 2.04% to 2496.00 yuan/ton [46] Key News (8.25-8.29) - The Ministry of Agriculture held a meeting to promote strict variety management, emphasizing the importance of new varieties and resource management [30] - The total output of aquatic products from January to July 2025 increased by 4.37% year-on-year, indicating a positive trend in the aquaculture sector [30] Subsector Financial Data - In H1 2025, the breeding, feed, poultry, and animal health sectors saw significant year-on-year profit growth, with breeding profits increasing by 668.38% [20][19] - The pet food sector also experienced a profit increase of 17.92% year-on-year, reflecting strong market demand [20][19]

养殖成本持续改善，业务稳健发展 天康生物(002100) 证券研究报告 饲料 / 公司点评 / 2025.08.31 | 投资评级:增持(维持) | | --- | | 基本数据 | 2025-08-29 | | --- | --- | | 收盘价(元) | 6.63 | | 流通股本(亿股) | 13.65 | | 每股净资产(元) | 5.15 | | 总股本(亿股) | 13.65 | 最近 12 月市场表现 相关报告 1. 《养殖成本延续下行，动保饲料经营稳 健》 2025-04-30 2. 《种群优化成本持续改善，养殖利润显弹 性》 2024-10-30 3. 《养猪成本下行业绩扭亏，饲料动保稳健 发展》 2024-08-30 核心观点 盈利预测 | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 19,026 | 17,176 | 16,960 | 17,859 | 18,642 | | 收入增长率 ...

Financial Performance - The company reported a total revenue of 8.847 billion yuan for the first half of 2025, representing a year-on-year increase of 10.68% [1] - The net profit attributable to shareholders reached 338 million yuan, up 22.27% year-on-year [1] - In Q2 2025, total revenue was 4.666 billion yuan, with a year-on-year increase of 10.68%, while net profit decreased by 14.59% to 190 million yuan [1] - The gross margin improved by 5.03% to 12.07%, and the net margin increased by 32.29% to 4.63% [1] - Total expenses (selling, administrative, and financial) amounted to 519 million yuan, accounting for 5.86% of revenue, a decrease of 13.04% year-on-year [1] Key Financial Ratios - Earnings per share (EPS) increased by 25% to 0.25 yuan [1] - Operating cash flow per share surged by 109.36% to 1.19 yuan [1] - The company's return on invested capital (ROIC) was 5.03%, indicating a generally weak capital return [3] - The net profit margin for the previous year was 3.47%, suggesting low added value for products or services [3] Debt and Cash Flow Analysis - The company had cash and cash equivalents of 2.973 billion yuan, a 3.87% increase year-on-year [1] - Interest-bearing liabilities decreased by 14.76% to 4.926 billion yuan [1] - The cash flow situation is a concern, with cash to current liabilities ratio at 59.75% [5] - The interest-bearing asset-liability ratio reached 30.33%, indicating a significant level of debt [5] Market Position and Investment Sentiment - The company has seen mixed performance in its historical financial reports, with two years of losses since its IPO [3] - Major funds have increased their holdings in the company, with the largest being Guotai CSI Livestock Breeding ETF, which holds 15.5491 million shares [6] - Analysts expect the company's performance for 2025 to reach 542 million yuan, with an average EPS forecast of 0.4 yuan [5]

格隆汇8月29日丨天康生物(002100.SZ)公布2025年半年度报告，上半年公司实现营业收入88.47亿元，同 比增长10.68%；归属于上市公司股东的净利润3.38亿元，同比增长22.27%；归属于上市公司股东的扣除 非经常性损益的净利润3.14亿元，同比增长16.17%；基本每股收益0.25元。 ...

智通财经APP讯，天康生物(002100.SZ)发布2025年半年度报告，该公司营业收入为88.47亿元，同比增 长10.68%。归属于上市公司股东的净利润为3.38亿元，同比增长22.27%。归属于上市公司股东的扣除非 经常性损益的净利润为3.14亿元，同比增长16.17%。基本每股收益为0.25元。 ...

证券日报网讯天康生物（002100）8月29日在互动平台回答投资者提问时表示，截至2025年8月20日收 盘，公司股份持有人数为68831户。 ...

天康生物股份有限公司 2025 年 半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 非经营性资金占用 资金占用方名 称 占用方与上 市公司的关 联关系 上市公司核算 的会计科目 2025 年期初 占用资金余 额 2025 年 1-6 月 占用累计发生 金额（不含利 息） 2025 年 1-6 月 占用资金的利 息（如有） 2025年1-6月 偿还累计发 生金额 2025年6月期 末占用资金 余额 占用形 成原因 占用性质 控股股东、实际控制 人及其附属企业 小计 - - - - 前控股股东、实际控 制人及其附属企业 小计 - - - - 其他关联方及附属企 业 小计 总计 - - - - 其它关联资金往来 资金往来方名 称 往来方与上 市公司的关 联关系 上市公司核算 的会计科目 2025 年期初 占用资金余 额 2025 年 1-6 月 占用累计发生 金额（不含利 息） 2025 年 1-6 月 占用资金的利 息（如有） 2025年1-6月 偿还累计发 生金额 2025年6月期 末占用资金 余额 往来形 成原因 往来性质 （经营性往来、 非经营性往来） 控股股东、实际控制 人及其附属企业 上 ...